Enhancement of placenta growth factor expression by oncostatin M in human rheumatoid arthritis synovial fibroblasts

Journal of Cellular Physiology

Volumn 228, Issue 5, 2013, Pages 983-990

  Tu, Huang Ju ^a   Lin, Tzu Hung ^a   Chiu, Yung Cheng ^b   Tang, Chih Hsin ^c   Yang, Rong Sen ^a   Fu, Wen Mei ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; MESSENGER RNA; ONCOSTATIN M; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; SERINE; STAT3 PROTEIN;

ANGIOGENESIS; ARTHRITIS; ARTICLE; CELL LEVEL; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; JOINT DESTRUCTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM;

ARTHRITIS, RHEUMATOID; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; JANUS KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; ONCOSTATIN M; PLACENTA; PREGNANCY; PREGNANCY PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL FLUID;

EID: 84873808428     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24244     Document Type: Article

References (49)

1. Aarvak T, Natvig JB. 2001. Cell-cell interactions in synovitis: Antigen presenting cells and T cell interaction in rheumatoid arthritis. Arthritis Res 3:13-17.
2. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. 2009. Type 17 T helper cells[mdash]origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 5:325-331.
3. Barnes TC, Moots RJ. 2009. Targeting oncostatin M in the treatment of rheumatoid arthritis. In: Tak P-P, editor. New therapeutic targets in rheumatoid arthritis. Basel: Birkhäuser. pp 181-191.
4. Bartok B, Firestein GS. 2010. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol Rev 233:233-255.
5. Boers M. 1990. Renal disorders in rheumatoid arthritis. Semin Arthritis Rheum 20:57-68.
6. Bottomley MJ, Webb NJ, Watson CJ, Holt L, Bukhari M, Denton J, Freemont AJ, Brenchley PE. 2000. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol 119:182-188.
7. Brusselle G. 2010. Rheumatoid arthritis and interstitial lung disease. Rheumatology 49:1425-1426.
8. Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, Spaull JR, Goldring MB, Koshy PJT, Rowan AD, Shingleton WD. 1998. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 41:1760-1771.
9. Choy EHS, Panayi GS. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916.
10. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. 1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803-1805.
11. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. 2005. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 23:795-800.
12. Di Poi E, Perin A, Morassi MP, Del Frate M, Ferraccioli GF, De Vita S. 2007. Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 25:85-87.
13. Dumas A, Lagarde S, Laflamme C, Pouliot M. 2012. Oncostatin M decreases interleukin-1 β secretion by human synovial fibroblasts and attenuates an acute inflammatory reaction in vivo. J Cell Mol Med 16:1274-1285.
14. El Mabrouk M, Sylvester J, Zafarullah M. 2007. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochim Biophys Acta (BBA)-Mol Cell Res 1773:309-320.
15. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ. 2006. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54:3152-3162.
16. Fiedler J, Leucht F, Waltenberger J, Dehio C, Brenner RE. 2005. VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. Biochem Biophys Res Commun 334:561-568.
17. Firestein GS. 2003. Evolving concepts of rheumatoid arthritis. Nature 423:356-361.
18. Gomez-Lechoz MJ. 1999. Oncostatin M: Signal transduction and biological activity. Life Sci 65:2019-2030.
19. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. 2006. Synovial fibroblasts: Key players in rheumatoid arthritis. Rheumatology 45:669-675.
20. Hui W, Bell M, Carroll G. 1997. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann Rheum Dis 56:184-187.
21. Innala L, Moller B, Ljung L, Magnusson S, Smedby T, Sodergren A, Ohman M-L, Rantapaa-Dahlqvist S, Wallberg-Jonsson S. 2011. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: A five year prospective study. Arthritis Res Ther 13:R131.
22. Khan S, Greenberg JD, Bhardwaj N. 2009. Dendritic cells as targets for therapy in rheumatoid arthritis. Nat Rev Rheumatol 5:566-571.
23. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285:1-24.
24. Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD. 2000. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 157:1187-1196.
25. Lanzillo B, Pappone N, Crisci C, Di Girolamo C, Massini R, Caruso G. 1998. Subclinical peripheral nerve involvement in patients with rheumatoid arthritis. Arthritis Rheum 41:1196-1202.
26. Lin T-H, Tang C-H, Wu K, Fong Y-C, Yang R-S, Fu W-M. 2011. 15-deoxy-Δ12, 14-prostaglandin-J2 and ciglitazone inhibit TNF-α-induced matrix metalloproteinase 13 production via the antagonism of NF-κB activation in human synovial fibroblasts. J Cell Physiol 226:3242-3250.
27. -ΔΔCT method. Methods 25:402-408.
28. Lutt JR, Deodhar A. 2008. Rheumatoid arthritis: Strategies in the management of patients showing an inadequate response to TNF[alpha] antagonists. Drugs 68:591-606.
29. Luttun A, Tjwa M, Carmeliet P. 2002. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1). Ann N Y Acad Sci 979:80-93.
30. Migita K, Komori A, Torigoshi T, Maeda Y, Izumi Y, Jiuchi Y, Miyashita T, Nakamura M, Motokawa S, Ishibashi H. 2011. CP690, 550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res Ther 13:R72.
31. Naka T, Nishimoto N, Kishimoto T. 2002. The paradigm of IL-6: From basic science to medicine. Arthritis Res 4:S233-S242.
32. O'Dell JR. 2004. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 350:2591-2602.
33. Olsen NJ, Stein CM. 2004. New drugs for rheumatoid arthritis. N Engl J Med 350:2167-2179.
34. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. 1994. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269:25646-25654.
35. Ribatti D. 2008. The discovery of the placental growth factor and its role in angiogenesis: A historical review. Angiogenesis 11:215-221.
36. Sakaguchi M, Oka M, Iwasaki T, Fukami Y, Nishigori C. 2012. Role and Regulation of STAT3 Phosphorylation at Ser727 in Melanocytes and Melanoma Cells. J Invest Dermatol 132:1877-1885.
37. Schuringa J-J, Wierenga ATJ, Kruijer W, Vellenga E. 2000. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95:3765-3770.
38. Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. 2003. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 102:1515-1524.
39. Shuai K, Liu B. 2003. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3:900-911.
40. Sims NA, Walsh NC. 2010. GP130 cytokines and bone remodelling in health and disease. BMB Rep 43:513-523.
41. Stoll JG, Yasothan U. 2009. Rheumatoid arthritis market. Nat Rev Drug Discov 8:693-694.
42. Tan T-W, Huang Y-L, Chang J-T, Lin J-J, Fong Y-C, Kuo C-C, Tsai C-H, Chen Y-J, Hsu H-C, Cho D-Y, Chen Y-H, Tang C-H. 2012. CCN3 increases BMP-4 expression and bone mineralization in osteoblasts. J Cell Physiol 227:2531-2541.
43. Tanaka M, Miyahima A. 2004. Onconstatin M, a multifunctional cytokine. Reviews of physiology, biochemistry and pharmacology. Berlin, Heidelberg: Springer. pp 39-52.
44. Tang C-H, Chiu Y-C, Tan T-W, Yang R-S, Fu W-M. 2007. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-κB pathway. J Immunol 179:5483-5492.
45. Tedder TF. 2009. CD19: A promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 5:572-577.
46. van Vollenhoven RF. 2007. Switching between anti-tumour necrosis factors: Trying to get a handle on a complex issue. Ann Rheum Dis 66:849-851.
47. Wang Q, Ma Y, Liu D, Zhang L, Wei W. 2011. The roles of B cells and their interactions with fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis. Int Arch Allergy Appl Immunol 155:205-211.
48. Yokogami K, Wakisaka S, Avruch J, Reeves SA. 2000. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10:47-50.
49. Yoo S-A, Yoon H-J, Kim H-S, Chae C-B, De Falco S, Cho C-S, Kim W-U. 2009. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: A link between angiogenesis and inflammation. Arthritis Rheum 60:345-354.